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INTRODUCTION
Biliary stent insertion is performed in patients with unre-
sectable malignant biliary ostruction as a palliative therapy 
to prevent early death due to deterioration of liver function 
or suppurative cholangitis.
1-3 A plastic stent insertion had 
been the standard of the endoscopic biliary drainage, but this 
method was limited by the fact that it needs to be replaced 
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every 3 to 4 months due to the stent occlusion or migration.
4 
Self expandable metal stent (SEMS) with longer patency than 
the conventional plastic stent was developed to address this 
limitation and has been in use since 1989.
5,6 An uncovered 
metal stent is advantageous in its low frequency of migration 
after the mesh was embedded with the tumor and the avail-
ability of using it in the intrahepatic bile duct; it is, however, 
associated with 20% to 40% incidence of early occlusion 
mainly due to the tumor ingrowth,
7-9 and is not available for 
replacement or removal once it was placed inside the bile 
duct.
10,11
Covered SEMS was developed to address these limitations 
and to prolong the patency, but it also has limitations, such 
as higher frequency of migration compared with the uncov-
ered metal stent
12 and the difficulty of stent repositioning 
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compared with those who had a plastic stent (94.6 days) (p=0.006). During the follow-up period, stent occlusion occurred in 11 patients 
of the covered SEMS group. Mean survival showed no significant difference between the two groups (covered SEMS group, 236.9 days; 
plastic stent group, 222.3 days; p=0.182).
Conclusions: The patency of the covered SEMS was longer than that of the plastic stent and the lasso of the covered SEMS was available 
for repositioning of the stent.
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once inserted inside the bile duct. We performed this multi-
center study to evaluate the clinical efficacy of a lasso-at-
tached covered SEMS insertion to prevent tumor ingrowth 
in patients with malignant biliary obstruction and to com-
pare the efficacy with the conventional 10 Fr plastic stent.
MATERIALS AND METHODS
Patients 
This study was performed in patients who were diagnosed 
of having an extrahepatic biliary stricture due to a malignant 
tumor and received the endoscopic retrograde biliary drain-
age (ERBD) at 7 university hospitals in South Korea from 
January 2005 to July 2006. These patients were unresectable 
or refused a surgery. A retrospective analysis was performed 
in 21 patients who received the covered SEMS insertion and 
23 patients who received the 10 Fr plastic stent insertion among 
those available for long-term follow-up.
Malignant biliary stricture was diagnosed base on sultra-
sonography, abdominal computed tomography (CT), mag-
netic resonance cholangiopancreatography, endoscopic ret-
rograde cholangiopancreatography (ERCP), and histological 
findings. Patients with hilarcholangiocarcinoma, history of 
biliary stent insertion, concomitant duodenal obstruction, or 
past history of gastrointestinal operation were excluded from 
the study. 
Methods
A 10-mm covered SEMS (Hanaro stent; M.I. Tech, Seoul, 
Korea), with lasso for location adjustment and silicone mem-
brane for the prevention of tumor ingrowth, was used for the 
metal stent group (Fig. 1). A 10 Fr polyethylene plastic stent 
(Wilson-Cook Medical, Winston-Salem, NC, USA) was used 
for the plastic stent group.
Conventional side viewing duodenoscopes (JF 240V, TJF 
240; Olympus Medical System Co., Tokyo, Japan) were used 
for ERCP in every patient. Endoscopic sphincterotomy (EST) 
was performed using a pull-type papillotome, and along the 
papillotome, a guide wire was inserted in the bile duct 
through the stricture site. The location and length of the 
stricture was assessed with the fluoroscopy, and then the 
stent was inserted along the guidewire. The Hanaro stent 
(M.I. Tech) was inserted across the stricture site into the ex-
trahepatic bile duct, along the guidewire, until the distal end 
was exposed about 1 cm from the major papilla to the duo-
denum. For the plastic stent, a guidewire was first inserted 
into the bile duct across the stricture site for the following 
guiding catheter insertion into the bile duct, and then the 
plastic stent was pushed across the stricture site using the pu-
sher catheter.
Technical success was defined when the stent was placed 
across the stricture and allowed the passing of the contrast 
media or the bile; while functional success was defined when 
the level of bilirubin decreased by 30% or more compared 
with the baseline level within a week or to a normal level 
within a month. Early or late complication was defined as 
any stent-related complication occurring within 30 days of or 
30 days after the insertion, and the procedure-related death 
was defined as deaths due to complications associated with 
the EST or stent insertion. Functional failure of the stent was 
defined as signs of acute cholangitis, such as abdominal pain, 
jaundice or fever; increase of bilirubin level; or radiologic 
(such as abdominal CT or US) evidence of stent occlusion. 
Stent patency was defined as the period between the date of 
stent insertion and the date of functional failure or death by 
disease progression. We also determined the cause and peri-
od of stent functional failure as well as the cause and time to 
death.
Statistical analysis
Chi-square test was performed for comparison of categori-
cal variables, and Student’s t-test for continuous variables. 
Stent patency and patient survival were calculated according 
to the Kaplan-Meier analysis, and comparison of stent paten-
cy and survival between the two groups were analyzed by the 
log-rank test. A p-value <0.05 was considered significant. 
Statistical analysis was performed using SPSS version 12.0 
(SPSS Inc., Chicago, IL, USA).
RESULTS
Among a total of 44 patients, 21 (10 males) were assigned 
to the Hanaro covered SEMS group and 23 (10 males) to the 
plastic stent group, and their mean age were 73.1±7.4 years 
(range, 60 to 88 years) and 65.7±13.2 years (range, 51 to 85 
years), respectively. Biliary obstruction was caused by chol-
Fig. 1. New developed covered Hanaro stent. Covered biliary 
stent with lasso. Lasso enables to correct the stent position when 
it’s misplaced.80  Clin Endosc 2012;45:78-83
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angiocarcinoma in 12 patients, pancreatic cancer in 6 pa-
tients, gallbladder cancer in 2 patients and ampullary cancer 
in 1 patient of the covered SEMS group; and by cholangio-
carcinoma in 9 patients, pancreatic cancer in 7 patients, gall-
bladder cancer in 4 patients and ampullary cancer in 3 pa-
tients of the plastic stent group, without a significant 
difference between the two groups (Table 1). The stricture 
site in the common bile duct was proximal in 2 patients, mid 
in 10 patients and distal in 9 patients of the covered SEMS 
group; proximal in 5 patients, mid in 4 patients and distal in 
14 patients of the plastic stent group.
Technical success rates were 95.2% (20/21) in the covered 
SEMS group and 100% (23/23) in the plastic stent group, 
without any significant difference between the two groups 
(p=0.290), except 1 case of technical failure due to the stent 
misplacement in the covered SEMS group, which was cor-
rected using forceps to catch the lasso and achieved the func-
tional success. Functional success rates were 90.5% (19/21) 
in the covered SEMS group and 91.3% (21/23) in the plastic 
stent group, without a significant difference between the two 
groups (p=0.924). The length of the Hanaro covered SEMS 
was selected among 5, 6, 7, 8, 9 or 10-cm length according to 
the length of the stricture, and the plastic stent among 5, 7, 9, 
10 or 12-cm length. The mean follow-up periods were 329.52 
±246.53 days (range, 4 to 908 days) in the covered SEMS 
group and 336.48±271.52 days (range, 88 to 1,189 days) in 
the plastic stent group. Early complications occurred in 3 pa-
tients from each group. In the covered SEMS group, mild 
pancreatitis occurred in 1 patient, cholangitis in 1 patient 
and cholecystitis in 1, and all of them were recoverd with 
conservative treatment. In the plastic stent group, mild pan-
creatitis occurred in 1 patient and the patient was recovered 
with conservative treatment, but 1 patient of cholangitis re-
quired covered SEMS insertion and another patient of the 
cholangitis was treated with percutaneous transhepatic bili-
ary drainage (PTBD) (Table 2).
The mean patency duration was significantly longer in the 
covered SEMS group (233.6 days; range, 21 to 660 days) 
compared with the plastic stent group (94.6 days; range, 4 to 
549 days) (p=0.006) (Table 2, Fig. 2).
The causes of stent occlusion in the covered SEMS group 
were bile sludge in 4 patients, tumor ingrowth in 4 patients, 
tumor overgrowth in 1 patient, stent migration in 1 patient 
and unknown origin in 1 patient. Among them, 9 patients 
were treated with plastic stent insertion inside the SEMS 
(n=4), metal stent insertion (n=4) and PTBD (n=1). In the 
plastic stent group, the causes of stent occlusion were bile 
sludge in 6 patients, tumor overgrowth in 2 patients, late 
stent migration in 2 patients and unknown origin in 1 pa-
tient, which were treated with metal stent insertion after re-
Table 1. Baseline Characteristics of the Patients with Unresect-
able Malignant Biliary Obstruction
Hanaro stent (n=21) Plastic stent (n=23)
Age (yr, range) 73.1±7.4 (60-88) 65.7±13.2 (51-85)
Male/Female 10/11 10/13
Diagnosis  
Bile duct cancer 12 9
Pancreatic cancer 6 7
Ampullary cancer 1 3
Gallbladder cancer 2 4
Values are presented as mean±SD.
Table 2. Outcome for Patients with Stent Placement
Hanaro stent  Plastic stent  p-value
Technical success rate (%) 20/21 (95.2)a) 23/23 (100.0) 0.290
Functional success rate (%) 19/21 (90.5) 21/23 (91.3) 0.924
Early complication   
Pancreatitis 1 1
Cholangitis 1 2
Cholecystitis 1 0
Mean stent patency (range), day 233.6 (21-660) 94.6 (4-549) 0.006
Cause of obstruction
Bile clogging 4 6
Tumor ingrowth 4 0
Tumor overgrowth 1 2
Stent migration 1 2
Unknown 1 1
Mean survival (range), day 236.9 (4-673) 222.3 (12-647) 0.182
a)One case that had failed technically, was repositioned successfully using lasso.JM Choi et al. 
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moving the plastic stent (n=6), re-insertion of the plastic 
stent (n=3) and PTBD (n=2) (Table 2).
Mean survival was 236.9 days (range, 4 to 673 days) in the 
Hanaro stent group and 222.3 days (range, 12 to 647 days) in 
the plastic stent group. There was no significant difference in 
the mean survival between the two groups (p=0.182) (Fig. 3).
DISCUSSION
ERBD is effective in the prevention and treatment of chol-
angitis and enables physiologic drainage of the bile, making 
it a suitable palliative therapy for patients with unresectable 
malignant biliary obstruction.
2,13 The indications of ERBD 
include malignant biliary obstruction due to pancreatic can-
cer or cholangiocarcinoma, suppurative cholangitis, com-
mon bile duct stone impaction, bile duct stricture after sur-
gery, and obstructive jaundice concomitant with chronic 
pancreatitis. In malignant biliary obstruction, the placement 
of biliary plastic stent rapidly improves the jaundice and al-
lows semi-permanent biliary drainage in unresectable cases. 
However, the plastic stent is not permanent and requires re-
placement or additional stent insertion in several months when 
the occlusion occurs. Efforts have been made to reduce the 
stent occlusion, such as by decreasing bacterial adhesion inside 
the stent or by changing the material or structure-size and 
shape, that is-of the stent,
14 without an apparent success yet.
Plastic stent is not expensive and replaceable, but requires 
frequent replacement due to the stent migration or frequent 
occlusion leading to the recurrence of obstructive jaundice 
or cholangitis.
8,15 Metal stent was developed in 1989 to over-
come these limitations and has been in use since then.
5,6 
SEMS is associated with less occlusion and cholangitis and 
shorter duration of hospital stay compared with the plastic 
stent.
7,8 The plastic stent induces occlusion mostly by the for-
mation of biliary sludge. The metal stent, however causes oc-
clusion mostly by the tumor ingrowth, where the tumor grows 
through the gaps of the stent mesh; by the tumor overgrowth, 
where the tumor grows to the upper and lower space of the 
stent; and by epithelial hyperplasia inside the stent.
16,17 The 
rate of metal stent occlusion due to the tumor ingrowth or 
overgrowth after some time, has been reported variously from 
7% to 42%.
5,10,18-20
According to a prospective trial by Davids et al.,
7 the early 
efficacy of drainage by the plastic stent and the metal stent 
are not significant different at 95% and 96%, respectively. 
This study also revealed no difference of the early efficacy by 
the materials of the stents, with the polyethylene plastic stent 
and the Hanaro covered SEMS respectively showing 91.3% 
(21/23) and 90.5% (19/21) of functional success rates. Given 
the fact that a stent of 7 Fr or more is physiologically suffi-
cient to induce biliary drainage,
21 this lack of difference in the 
early efficacy of drainage between the plastic stent group and 
the Hanaro covered SEMS group in our study may come 
from using 10 Fr plastic stents. The time to biliary stent oc-
clusion of a 10 Fr plastic stent has been reported average 134 
to 164 days.
22,23 Davids et al.
7 reported stent patency of 273 
days for metal stent (Wallstent; Schneider, Minneapolis, MN, 
USA) and 126 days for polyethylene plastic stent in distal 
malignant biliary obstruction. Our findings also showed 
233.6 days and 94.6 days of mean stent patency for the Han-
aro covered SEMS group and the plastic group, respectively.
The advantage of the SEMS is that the stent diameter can 
be increased remarkably to allow early sufficient drainage, 
the duration of patency is longer than the plastic stent, and 
the frequency of migration is low.
7 But several disadvantages 
of the SEMS have been also pointed out, including the diffi-
culty of insertion technique compared with that of the plastic 
stent,
24 the possibility of injuries such as bleeding or perfora-
tion in the duodenum and the papilla,
25 high cost, inability to 
remove once placed, and the possibility of stent occlusion 
due to the tumor ingrowth or overgrowth.
26 Despite the de-
velopment of covered SEMS, using a thin layer of polyure-
thane, silicon, polytetrafluoroethylene or Gore-Tex to cover 
Fig. 3. Patients survival after stent insertion. The survival was not 
significantly different between two groups (p=0.182).
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SEMS (30 Fr), to prevent functional failure due to the tumor 
ingrowth or overgrowth, tumor ingrowth is still reported to 
occur with the membrane covered metal stent.
27-30 Suh et al.
31 
reported, in a study of 59 patients who were diagnosed with 
extrahepatic biliary stricture due to the malignant tumor, 
that the tumor ingrowth was the cause of the stent functional 
failure in 6.6% (2/29) of the covered SEMS group compared 
to 24% (7/30) of the uncovered SEMS group, suggesting that 
the covered SEMS may prevent the tumor ingrowth effi-
ciently. The functional failure of the Hanaro covered SEMS 
in our study was due to stent occlusion in 9 patients and of 
migration in 1 patient (late stent migration); among these 9 
patients of occlusion, 4 patients (44.4%) were associated with 
the tumor ingrowth, 1 patient with the tumor overgrowth, 
and the remaining 4 patients with the biliary sludge, reflect-
ing that the covering membrane of the SEMS cannot prevent 
the tumor ingrowth completely. Tumor ingrowth in the cov-
ered SEMS may occur when the membrane was damaged 
during the stent insertion, by the bile or biliary stone, or by 
bacterial infection, but little data are available regarding the 
exact cause of tumor ingrowth.
Early complications occurring during the stent insertion 
or within 2 weeks after the insertion include cholangitis, cho-
lecystitis, perforation, bleeding, and acute pancreatitis, at 
6.4% to 26.3% of incidence, among which cholangitis occur-
ring most frequently.
22 Davids et al.
7 reported that 11% of the 
plastic stent group and 12% of the metal stent group were as-
sociated with the early (within a week after the stent inser-
tion) complications, which is similar to our results of 12.5% 
(3/23) for the plastic stent group and 14.3% (3/21) for the 
Hanaro covered SEMS group. Isayama et al.
32 reported that 
the membrane attached to a stent often blocks the orifice of 
the cystic duct or the pancreatic duct causing cholecystitis or 
pancreatitis. In this study, there were 3 cases of early compli-
cations in the both groups, repectively. In the Hanaro cov-
ered SEMS group, there were pancreatitis in 1 patient, chol-
angitis in 1 patient and cholecystitis in 1 patient, all of them 
were recovered with conservative treatment. In the plastic 
stent group, pancreatitis occurred in 1 patient and cholangi-
tis in 2 patients; the former was recovered with conservative 
treatment, while each of the patients with cholangitis re-
quired SEMS insertion and PTBD, respectively.
There is still a controversy in what type of stent should be 
used for ERBD in terms of cost-effectiveness. Prat et al.
33 re-
ported 3.2 months of survival for ≥30 mm of tumor diameter 
and 6.6 months of survival for ≤30 mm of tumor diameter in 
101 patients with unresectable malignant biliary obstruction. 
Therefore, they insisted that the metal stent may be more ef-
fective than the plastic stent when the tumor diameter is 30 
mm or less in unresectable malignant biliary obstruction.
33 
Schmassmann et al.
17 also reported that the metal stent was 
more effective than the plastic stent in patients with more 
than 6 to 9 months of life expectancy.
Cahen et al.
34 emphasized that modification of the SEMS 
design was necessary for convenient removal and reposition-
ing of the stent. The lasso attached on the covered SEMS in 
our study allowed functional success in 1 case of technical 
failure during the insertion by enabling the stent reposition-
ing at ease.
In conclusion, the placement of the covered SEMS with 
longer stent patency seemed to be more effective than that of 
the plastic stent in patients with unresectable malignant bili-
ary obstruction who their life expectancy are estimated to be 
longer than 6 to 9 months based on their general condition, 
the presence of comorbidity and biliary stricture diameter. 
The lasso of the covered SEMS seemed to be helpful in repo-
sitioning of the stent to achieve functional success, although 
this issue needs to be further studied in prospective studies 
with more cases.
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